Floatz logo

e39 peptide vaccine

Fallopian Cancer

COL George Peoples, MD, FACSvaccinePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Fallopian Cancer cohort.

Asset / SponsorPhaseRating
Enmd-2076
CASI pharmaceuticals, Inc.
Phase 2B
FULVESTRANT
Atavistik Bio, Inc
Phase 1/2CCC
J65
COL George Peoples, MD, FACS
Phase 1/2CCC
Atv-1601
Atavistik Bio, Inc
Phase 1CC

Same molecule, other indications

e39 peptide vaccine is also rated in:

ovarian cancerDormant
CCC
Indicative ·
52 / 100
View asset →
Peritoneal CancerDormant
CCC
Indicative ·
48 / 100
View asset →
Endometrial CancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →